Science Spotlight: Reducing immune rejection of stem cell-derived therapies

ARTICLE | Discovery & Translation

BioCentury’s roundup of translational innovation also includes a new target for arrhythmia and four papers with links to newcos

By Danielle Golovin, Senior Biopharma Analyst

November 27, 2024 11:13 PM UTC

Collaborators from Medical University of South Carolina and University of Florida, including Tolerance Bio Inc. co-founder Holger Russ, reported a method to reduce immune-mediated rejection of beta cell replacement therapy.

The team edited human pluripotent stem cells to express an inert bait protein, a truncated version of EGFR, and engineered regulatory T cells (Tregs) to express a CAR that binds to the bait.